Publications by authors named "Mark A Killick"

Claim this Profile
I
Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVC) covalently complexed to two-domain CD4 elicits cross-clade neutralizing antibodies in New Zealand white rabbits.
Nancy L Tumba, Gavin R Owen, Mark A Killick, Maria A Papathanasopoulos

Vaccine X· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6.
Tumelo Moshoette, Maria Antonia Papathanasopoulos, Mark Andrew Killick

Virol J· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Covalent binding of human two-domain CD4 to an HIV-1 subtype C SOSIP.664 trimer modulates its structural dynamics.
Nancy L Tumba, Previn Naicker, Stoyan Stoychev, Mark A Killick, Gavin R Owen

Biochem Biophys Res Commun· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1.
Tumelo Moshoette, Stuart Alvaro Ali, Maria Antonia Papathanasopoulos, Mark Andrew Killick

Retrovirology· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).
Mark A Killick, Michelle L Grant, Nichole M Cerutti, Alexio Capovilla, Maria A Papathanasopoulos

Vaccine· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis